JP Morgan 2025: Incyte expects period of ‘defining catalysts’
Incyte announced plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD.
Corporate Governance
FDA CDER director Patrizia Cavazzoni announces resignation
Eli Lilly’s UK life sciences investment ‘a pivotal moment’, says analyst
Nobel laureates ‘strongly urge’ Senate to oppose confirmation of RFK Jr
Vifor Pharma offers £23m to NHS to resolve CMA investigation
FDA shares new draft guidance for accelerated approval
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Trump 2.0 could see a rise in biopharmaceutical M&A deals
